Yes, tazarotene 0.045% lotion—marketed as ARAZLO—is notably more tolerable than previous tazarotene formulations, particularly compared to the older 0.1% cream that dermatologists have used for decades. The key difference lies in its lotion-based delivery system and lower concentration. Clinical trials showed that only 2.9% of patients using the 0.045% lotion experienced adverse events, compared to 5.6% of those using the older 0.1% cream.
This represents a 48% reduction in side effects while maintaining significant efficacy against acne. The FDA approved ARAZLO on December 19, 2019, making it the first tazarotene acne treatment available in lotion form. The lotion formulation uses a polymeric emulsion technology—an oil-in-water emulsion with hydrating ingredients trapped within a honeycomb matrix—that penetrates more gently into skin while delivering the active ingredient effectively. Unlike previous tazarotene creams that often caused irritation, redness, and peeling, this new formulation was designed specifically to minimize these common retinoid side effects while treating acne in patients as young as 9 years old.
Table of Contents
- How Is Tazarotene 0.045% Lotion Different From Other Retinoid Acne Treatments?
- What Does the Clinical Evidence Show About Effectiveness?
- How Does the Lotion Formulation Reduce Side Effects?
- What Are the Specific Side Effects Patients Should Expect?
- What Limitations Should Patients Know Before Starting?
- How Should Patients Use Tazarotene 0.045% Lotion for Best Results?
- Insurance Coverage and Practical Access to ARAZLO
- Conclusion
How Is Tazarotene 0.045% Lotion Different From Other Retinoid Acne Treatments?
Tazarotene belongs to a class of medications called retinoids, which are vitamin A derivatives that work by normalizing skin cell turnover and reducing inflammation. What distinguishes the 0.045% lotion from other retinoid options—and from earlier tazarotene formulations—is its formulation and concentration. The lotion-based vehicle allows for better spreadability across the skin and faster absorption compared to creams, which tend to sit on the surface and cause the irritation that users have complained about for years. The older tazarotene 0.1% cream was highly effective but came with a steep tolerance cost.
Many patients reported burning, stinging, excessive dryness, and peeling so severe they had to stop treatment. The 0.045% lotion achieves similar efficacy—reducing inflammatory acne lesions by 55.5% to 59.5% in clinical trials—while causing significantly fewer tolerability issues. This makes it a realistic option for patients with sensitive skin who might have abandoned retinoid therapy in the past. For example, a patient who previously couldn’t tolerate tretinoin or the older tazarotene cream might find they can successfully use this lotion without experiencing unbearable side effects.
What Does the Clinical Evidence Show About Effectiveness?
The FDA approval of ARAZLO was based on two identical Phase 3 clinical trials involving 1,614 subjects treated over 12 weeks. These weren’t small studies or preliminary findings—they represented rigorous, double-blind, randomized testing against a placebo vehicle to demonstrate real efficacy. The first study showed a mean reduction of 55.5% in inflammatory lesions and 51.4% in noninflammatory lesions. The second study achieved even stronger results: 59.5% reduction in inflammatory lesions and 60% reduction in noninflammatory lesions.
Beyond these average reductions, the trials measured “treatment success”—defined as achieving clear or almost clear skin by the end of 12 weeks. In Study 1, 25.5% of subjects achieved this outcome; in Study 2, 29.6% did. While these success rates might sound modest compared to some newer acne medications, they’re consistent with what dermatologists see in real-world practice with prescription-strength retinoids. The data also demonstrated that benefits continued accumulating throughout the 12-week period, meaning patients likely needed to stick with treatment for at least 8-12 weeks before seeing maximum improvement—a critical point to manage patient expectations.
How Does the Lotion Formulation Reduce Side Effects?
The polymeric emulsion technology used in ARAZLO is the engineering breakthrough that makes this formulation different. Traditional retinoid creams rely on heavy emollients and waxes that can trap heat and irritating ingredients on the skin surface, causing the intense burning and peeling that makes patients quit treatment. The lotion formulation traps hydrating ingredients in a honeycomb matrix structure, allowing tazarotene to be absorbed more evenly and gradually while moisturizing ingredients work alongside it to buffer irritation.
This approach directly resulted in lower adverse event rates. The most commonly reported side effects in the clinical trials were application site pain (5.3%), dryness (3.6%), and exfoliation (2.1%)—all significantly lower than historical rates with older formulations. When tazarotene 0.045% lotion was tested head-to-head against tazarotene 0.1% cream, the lotion demonstrated superior tolerability. These weren’t trivial improvements; for patients with sensitive skin, reactive skin, or those who live in cold, dry climates where retinoid irritation is magnified, this difference can mean the difference between staying on treatment and abandoning it after two weeks.
What Are the Specific Side Effects Patients Should Expect?
The most common complaint with tazarotene 0.045% lotion is application site pain, which sounds concerning until you understand what it means in practice: a mild stinging or burning sensation at the site where you apply the medication, typically lasting a few minutes. This occurred in only 5.3% of trial participants and was usually mild to moderate rather than severe. Dryness and exfoliation are more frequent concerns with any retinoid, appearing in 3.6% and 2.1% of users respectively, but these are manageable with proper moisturizing and sun protection rather than reasons to stop treatment.
It’s important to note what didn’t happen in the clinical trials: dermatological safety studies specifically tested ARAZLO’s potential for irritancy and contact dermatitis and found the formulation had low sensitizing potential. It did not induce sensitization in Phase 1 dermal safety testing, which is reassuring for long-term use. However, this doesn’t mean there’s zero risk of irritation—retinoids inherently cause some level of irritation as they work—but the risk is substantially lower than with previous options. Patients starting this medication should still begin with the lowest frequency (perhaps twice or three times weekly) and gradually increase to once-daily application as their skin adapts, contrary to what the label suggests.
What Limitations Should Patients Know Before Starting?
Despite its improved tolerability, tazarotene 0.045% lotion is not appropriate for everyone and has genuine limitations. Pregnant women cannot use it; tazarotene is in FDA Pregnancy Category C (now Category X under newer guidelines), meaning it carries potential risk to the fetus. Women of childbearing age using this medication should use reliable contraception and understand this restriction clearly. Additionally, while approved for ages 9 and up, it’s rarely prescribed to children that young in practice, as compliance and proper use are challenging in that age group.
The medication also requires consistent sun protection—retinoids increase photosensitivity, making skin more vulnerable to sun damage and increasing the risk of sunburn. Many patients don’t take this warning seriously and end up with significant sun sensitivity or hyperpigmentation. Another limitation: tazarotene takes 8-12 weeks to show maximum effect, and some patients see initial worsening of acne (called “retinization”) in weeks 1-3 before improvement occurs. Patients expecting immediate results often discontinue prematurely, missing the actual benefit. Finally, while 29.6% achieved clear skin, that means over 70% of users experienced improvement but not complete clearing, so realistic expectations about what this medication can accomplish are essential.
How Should Patients Use Tazarotene 0.045% Lotion for Best Results?
ARAZLO is applied directly to affected acne areas once per day as a thin layer. The word “thin” is crucial—many patients apply too much, thinking more will work faster, when actually a pea-sized amount is sufficient for the entire face. Application should occur at night, as retinoids work best when not exposed to sunlight and when the skin barrier is naturally repairing itself during sleep. The skin should be completely dry before application (waiting 20 minutes after cleansing is a good practice), as applying retinoids to damp skin dramatically increases irritation.
The critical modification many dermatologists recommend: start with lower frequency than the label suggests. Begin with application 2-3 times per week for the first 2-4 weeks, then gradually increase to every other night, then nightly over the course of 4-8 weeks. This “start low, go slow” approach reduces the likelihood of severe irritation that causes patients to quit. Daytime use requires SPF 30 minimum (SPF 50+ is better), reapplied every two hours if outdoors. Patients should avoid other potentially irritating medications during the first month of treatment—meaning no vitamin C serums, benzoyl peroxide, or alpha hydroxy acids initially—and should use a gentle, fragrance-free moisturizer religiously.
Insurance Coverage and Practical Access to ARAZLO
As of 2024-2025, major insurance plans including Aetna and FEP Blue maintain pharmacy clinical policies for ARAZLO, meaning coverage is generally available but may require prior authorization. The prior authorization process typically requires documentation that the patient has tried and failed with other acne treatments or has a specific medical reason for needing this medication specifically. Without insurance, ARAZLO can cost $200-400 for a one-month supply, making it accessible primarily to those with coverage or means to pay out-of-pocket.
Generic tazarotene in older formulations (0.1% cream) remains available and significantly cheaper, but the tolerability difference is substantial enough that many dermatologists now prefer prescribing the newer 0.045% lotion when insurance allows. For uninsured or underinsured patients, generic tazarotene 0.05% or 0.1% creams available through larger pharmacy chains can cost $30-80 monthly, though they may require compounding at some pharmacies. The choice between brand ARAZLO and generic tazarotene often comes down to insurance coverage and individual skin sensitivity rather than significant differences in efficacy.
Conclusion
Tazarotene 0.045% lotion represents a genuine advancement in retinoid-based acne treatment, delivering the proven efficacy of tazarotene (55-60% reduction in acne lesions over 12 weeks) with substantially fewer side effects than previous formulations. The lotion-based polymeric emulsion technology was specifically engineered to address the tolerability problems that made older tazarotene creams difficult for many patients to use long-term. With adverse events occurring in only 2.9% of users compared to 5.6% with the older 0.1% cream, this medication opens retinoid therapy to patients who previously couldn’t tolerate these powerful medications.
If you’re considering tazarotene 0.045% lotion, discuss with your dermatologist whether your insurance will cover it and whether you’re a candidate for treatment. Understand that results take 8-12 weeks, that starting slowly with frequency is critical, and that consistent sun protection is non-negotiable. For many patients with moderate acne who have struggled with previous retinoid irritation, this medication offers a realistic path to clearer skin without the severe side effects that previously forced them to choose between acne and tolerability.
You Might Also Like
- New Study Found That Combining Microneedling With PRP Improved Acne Scars 50% More Than Microneedling Alone
- Fact Check: Is Bakuchiol a Good Retinol Alternative for Acne? Early Studies Show Promise but It’s Less Potent Than Tretinoin
- She Was a Swimmer Who Developed Chlorine-Induced Acne…Had to Choose Between Her Sport and Her Skin
